

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:  C12Q 1/37, G01N 33/533		A1	(11) International Publication Number: WO 94/28166  (43) International Publication Date: 8 December 1994 (08.12.94)
<p>(21) International Application Number: PCT/GB94/01153</p> <p>(22) International Filing Date: 27 May 1994 (27.05.94)</p> <p>(30) Priority Data: 9310978.3 27 May 1993 (27.05.93) GB</p> <p>(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): GARMAN, Andrew, John [GB/GB]; 15 Peel Hall Lane, Ashton, Chester CH3 8DE (GB).</p> <p>(74) Agents: PHILLIPS, Neil, Godfrey, Alasdair et al.; ICI Group Patents Services Dept., P.O. Box 6, Shire Park, Welwyn Garden City, Hertfordshire AL7 1HD (GB).</p>		<p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FL, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: FLUORESCENCE ENERGY TRANSFER SUBSTRATES</p> <p>(57) Abstract</p> <p>A method for the preparation of a fluorescence resonance energy transfer (FRET) substrate having donor and acceptor species on opposite sides of a proteolytic cleavage site and wherein the donor and/or acceptor species are attached via the side chain(s) of amino acid(s) therein. The method comprises contacting a reactive donor or acceptor species with a polypeptide substrate having the side chain(s) of amino acid(s) therein adapted for reaction with the reactive species and then contacting the substrate so obtained with a corresponding reactive donor or acceptor species. Novel FRET substrates so prepared and their use in assays to identify modulators of protease activity.</p>			

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Burkina	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	L1	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Tinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

### FLUORESCENCE ENERGY TRANSFER SUBSTRATES

The concept of the fluorescence energy transfer (FRET) substrate for hydrolytic enzymes was first suggested by Carmel et al. (FEBS Lett., 30, 11-14(1973)); they described a trypsin substrate using naphthyl as the donor and anthracene as the acceptor. Since then, several protease substrates have been described using this principle. In this approach the donor fluorophore and acceptor molecules are positioned either side of the bond to be cleaved and are sufficiently close such that a large proportion of the fluorescence of the donor fluorophore is quenched by radiationless energy transfer to the acceptor. Cleavage causes a large increase in separation of the donor and acceptor which is made manifest by an increase in fluorescence. Here the acceptor moiety does not need to be a fluorophore; the key requirement is that the absorption maximum should be the same as, or close to, the emission maximum of the donor fluorophore. Optionally, the acceptor may be itself a fluorophore, in which case the enzymic reaction may be followed by the decrease in energy transfer fluorescence of the acceptor fluorophore. A variety of donors and acceptors have been employed, a common pair is an "in-sequence" tryptophan as the donor and dansyl as the acceptor. Energy transfer substrates are particularly useful for proteases that have significant recognition in the native substrate of amino acids C-terminal to the cleavage site; other proteases that do not have such recognition sites are conveniently measured using peptides with fluorogenic or chromogenic leaving groups.

Present FRET substrates are limited to fluorophores that require UV excitation. This limits their use especially in compound screening methods. Furthermore the donor and/or acceptor species are attached during synthesis of the peptide substrate. This generally requires specialist reagents and know-how relating to their use. Accordingly a range of donor and acceptor species cannot be readily assessed for a given substrate.

Wang et al (Tet. Lett., 1990, 13, 6493-6496) describe a

- 2 -

method for the preparation of fluorogenic HIV protease substrates which involves the addition of donor and acceptor species to the N- and C- termini of a peptide substrate. However, as the authors acknowledge, the procedures followed which include fluorophore attachment to the C- terminus are not straightforward. Overall this paper does not disclose a generally applicable approach.

Maggiora et al (J. Med. Chem. 1992, 35, 3727-3730) describe a method for the synthesis of FRET substrates which employs a (donor) EDANS labelled glutamic acid derivative which is introduced during peptide synthesis. The disadvantage of this approach is that, if for example for reasons of poor activity, the EDANS derivative does not give a useful substrate, then a different amino acid derivative needs to be prepared and the peptide synthesised afresh. Selecting the optimum donor is therefore not straightforward.

We have now devised a novel and advantageous method for preparing FRET protease substrates wherein, after synthesis of the polypeptide substrate, a donor or acceptor is attached via the side chain of an amino acid comprised in the polypeptide. This allows a wide range of donor and acceptor pairs, many of which are commercially available, to be attached to the peptide structure. Accordingly, desirable donor and acceptor combinations may be readily selected.

In a first aspect of the present invention we provide a method for the preparation of a polypeptide substrate for proteolytic cleavage and having a donor or acceptor species attached via a side chain of an amino acid therein which method comprises contacting an appropriate reactive donor or acceptor species with a polypeptide substrate having a side chain of an amino acid therein adapted for reaction therewith.

The above method is preferably used to prepare FRET protease substrates having appropriate donor and acceptor species on opposite sides of a proteolytic cleavage site. This is achieved either by prior or subsequent reaction of the polypeptide substrate with the

- 3 -

corresponding reactive donor or acceptor species. By "corresponding" we mean that if a donor is attached first, then a suitable energy transfer acceptor is subsequently attached or vice versa. If desired both donor and acceptor species may be attached via the side chains of amino acids therein.

The polypeptide substrate is conveniently prepared by direct synthesis, for example as outlined in Solid Phase Peptide Synthesis, E Atherton and R C Sheppard, IRL Press, 1989. The polypeptide substrate may comprise natural or non-natural (for example D-) amino acids joined by natural or modified peptide linkages, or any combination thereof.

The sites on the polypeptide substrate for attachment of reactive donor and acceptor species are conveniently provided by amino and thiol groups. More conveniently these groups are comprised in the N-terminus and the side chain of a cysteine residue respectively. Where no appropriate group is naturally present in the sequence, this may be introduced at any convenient point, preferably by replacement of a non-critical residue. By way of example the thiol group may be introduced by replacement of a non-critical residue by cysteine. It will be clear that by "adapted for reaction" we include amino acids which are either inherently adapted for reaction or chemically modified.

Alternatively, the sites on the polypeptide substrate may be provided by introduction of chemically modified residues during peptide synthesis. By "attachment via the side chain of an amino acid" we therefore include attachment via a side chain of any amino acid, whether modified or replaced by any convenient chemical linkage. We do not exclude attachment via any convenient linkage replacing the hydrogen atom at the  $\alpha$ -carbon of the amino acid residue.

It will be appreciated that the donor and acceptor species and their means of attachment are selected such that proteolytic cleavage of the substrate is not affected to any significant extent.

- 9 -

In general, the N-terminus of the selected peptide is chosen to be a sufficient distance from the site of proteolytic cleavage such that its modification does not significantly affect activity. This will vary from enzyme to enzyme, however, by way of example, the N terminus is conveniently at least 3 amino acids from the cleavage site, more conveniently more than 5. Likewise the point of attachment for the donor/acceptor on the side chain is selected so as not to significantly affect activity. This will also vary according to the enzyme, but by way of example, it should be at least 3, preferably 5 amino acids away from the site for proteolytic cleavage. The total distance between attachment sites needs to be such that a useful amount of energy transfer can occur. Whilst we do not wish to be bound by theoretical considerations, this will depend on the 3 dimensional conformation adopted by the peptide in solution. The worst case can be predicted by assuming both a linear structure, and that each amino acid accounts for 3.8 angstroms. Hence for 50% energy transfer and assuming a favourable alignment of dipoles, the number of amino acids separating the donor and acceptor should be less than  $R_0/3.8$ , where  $R_0$  is the distance giving 50% transfer. For a fuller discussion, see for example J.R. Lakowicz, Principles of Fluorescence Spectroscopy, Plenum, 1983. Appropriate experiments for determining the optimum positions for attachment of the donor and acceptor species will be apparent to the scientist of ordinary skill.

Where amino and thiol chemistry is employed, the polypeptide substrate is conveniently firstly contacted with a donor or acceptor species so as to attach this via the side chain of an amino acid therein. The resulting substrate is then contacted with a corresponding donor or acceptor species so as to provide a FRET protease substrate.

Therefore in a preferred aspect of the present invention we provide a method for the preparation of a FRET protease substrate having donor and acceptor species on opposite sides of a proteolytic cleavage site which method comprises contacting a polypeptide substrate having a side chain of an amino acid therein adapted via a

- 3 -

thiol group for reaction with an appropriate reactive donor or acceptor species and then contacting an amino group of the substrate so obtained with an appropriate reactive donor or acceptor species.

Convenient reagents for reaction at thiol groups include donor/acceptors derivatised with maleimido or haloacetyl groups. These may be reacted at typically neutral or moderately alkaline pH, conveniently in stoichiometric amounts. Purification of the peptide derivative away from excess reagent, if present may conveniently be achieved for example by gel filtration or reverse phase hplc. Other methods, for example extraction, may be devised.

Convenient reagents for reaction at amino groups include donor/acceptors derivatised with isothiocyanates, active esters, such as succinimidyl esters, of carboxylic acids or sulphonyl halides. These are generally reacted at moderately alkaline pH in an excess over the peptide. Purification may be achieved for example by gel filtration or reverse phase hplc. Other methods, for example extraction, may be devised by the person of ordinary skill.

Convenient donor and acceptor reagents for use in the methods of the invention will be apparent to the chemist of ordinary skill. Such species include those disclosed in "Molecular Probes: Handbook of Fluorescent Probes and Research Chemicals" - Richard P. Haugland - Molecular Probes Inc. If a desired reagent is not commercially available its synthesis will be evident to the above chemist of ordinary skill.

If desired only one type of group is required to achieve attachment of donor and acceptor species. By way of example only amino or thiol groups, conveniently thiol groups are required. Addition of approximately equimolar amounts of appropriate donor and acceptor reagents provides a mixture comprising about 50% of the desired substrate.

The above methods may be applied to any convenient substrate

for proteolytic cleavage. A particular substrate is big endothelin. It will be appreciated that any convenient part of a substrate sequence may be used provided that the recognition site(s) and site for proteolytic cleavage are present. As convenient example is big endothelin [16-38].

The above methods may be applied to the synthesis of substrates for any suitable protease, for example trypsin, chymotrypsin, elastase, thrombin, endothelin converting enzyme, angiotensin converting enzyme, HIV protease, matrix degrading proteases, collagenases, pro-hormone processing enzymes, pro-cytokine 1, growth factor processing enzymes and signal peptidases.

It will be understood that more than one donor and acceptor species may be provided on the FRET protease substrate although in practice more than two pairs is less convenient.

In a further aspect of the present invention we provide a FRET protease substrate when prepared by the method of the invention.

It will be clear from the above that the present invention allows a wide range of donor and acceptor pairs to be readily attached to the peptide structure, enabling the most suitable pair to be selected. Factors that may be considered in this selection include the level of activity obtained, the degree of energy transfer (which will determine the initial level of fluorescence of the substrate) and the excitation and emission wavelengths of the donor or acceptor.

A particular use of the present invention is in the provision of FRET protease substrates for compound screening, for example in pharmaceutical and agrochemical areas as well as more general research. For these procedures the absorption wavelengths of the majority of test compounds are preferably avoided.

It will be appreciated that the FRET protease substrates of the invention may be used in a variety of homogeneous and

- 7 -

heterogeneous assays for testing compounds individually or as mixtures.

In a further aspect of the present invention we provide a FRET protease substrate comprising a visible light fluorophore. The fluorophore is preferably attached after synthesis of the polypeptide chain of the protease substrate. The visible light fluorophore is more preferably attached via a side chain of an amino acid comprised in the polypeptide chain. Suitable visible light fluorophores (excitation maximum of the donor above about 350 nm) include fluorescein, Lucifer Yellow, acridine Orange, rhodamine and its derivatives, for example tetramethylrhodamine and Texas Red, and fluorescent chelates or cryptates of Europium. A preferred fluorophore is fluorescein.

Suitable energy transfer pairs may be found in the literature, for example in Applications of Fluorescence in Immunoassays (I.A. Hemmila, Wiley Interscience, 1991) or may be devised by a person of ordinary skill in accordance with energy transfer principles for example as outlined by J.R. Lakowicz, Principles of Fluorescence Spectroscopy, Plenum, 1983.

The method of the invention will now be illustrated but not limited by reference to the following:

1. A desired peptide sequence is selected which encompasses the site for proteolytic cleavage.
2. A position C-terminal to the site which can be mutated to cysteine and used as an attachment site without loss of substrate activity is selected.
3. The above peptide is synthesised with:
  - a) a free N-terminus (the C-terminus can be free or amidated as required);

- 8 -

b) any lysines C-terminal to the site for proteolytic cleavage or considered to be non-tolerant with respect to enzyme activity is either "mutated" to a non-reactive analogue (eg. arginine or dimethyl lysine) or reversibly protected;

c) any lysines N-terminal to the site for proteolytic cleavage may be treated as above or, if they are considered to be tolerant to conjugation, can be left in place (in which case the N-terminus may be modified if desired);

The peptide now has one or more amino groups on one side of the cleavage site and a unique thiol on the other side. A wide range of thiol reactive and amino reactive derivatives of fluorophores and acceptor molecules are available commercially, including many that operate in the visible region of the spectrum. With the above peptide it is therefore possible to synthesise a range of convenient energy transfer substrates with different pairs and in different orientations.

Where big endothelin [16-38] is used as the FRET protease substrate the above complications do not apply since there are no lysines. We have evidence that for this substrate the choice of donor-acceptor pair has a significant effect on activity and that therefore the ability to screen different pairs and orientations is very useful.

Peptides containing free cysteines are unlikely to be common but we anticipate that these can be accommodated in an analogous fashion to the approach described above for lysine.

The invention will now be illustrated but not limited by reference to the following Examples and Figures.

Figure 1 illustrates the course of two reactions as measured with respect to time (x-axis) and fluorescence units (Y-axis). In the first of these only substrate A is added to the reaction mixture .

- 9 -

whereas in the second both substrate A and enzyme are added. Phosphoramidon is added to terminate this second, enzyme catalysed, reaction.

Figure 2 shows the increase in fluorescence obtained over time using substrate D as substrate for the staphylococcal V8 protease (cf. Example 2). The reaction plateaus at a level ca 6.3 times higher than the initial level. Assuming complete conversion of substrate during the incubation, this imples that the substrate D was ca 84% quenched.

- 10 -

Example 1

Preparation of the starting peptide

The peptide sequence selected was derived from that of human big endothelin-1, 16-37, with Glu-26 changed to Cys:

H.His.Leu.Asp.Ile.Ile.Trp.Val.Asn.Thr.Pro.Cys.His.Val.Val.Pro.Tyr.Gly.  
Leu.Gly.Ser.Pro.Arg.OH

This peptide (peptide I) was synthesised on a polyamide support using conventional Fmoc chemistry, as described in Solid Phase Peptide Synthesis, E Atherton and R C Sheppard, IRL Press, 1989.

Preparation of ([Cys-26]fluoresceinyl) peptide I

To a solution of peptide I in water (2mg/ml), was added an equimolar amount of 5-maleimidofluorescein (Molecular Probes, added as 5 mM solution in DMSO). After 10 minutes, 0.3 volumes of 0.1M NaHCO<sub>3</sub>, 0.9t NaCl buffer pH 8.5 added. After a further 10 minutes a sample was assayed for thiol content using Ellman's reagent. The thiol content was found to be zero indicating complete coupling.

Preparation of tetramethylrhodaminyl ([Cys-26]fluoresceinyl) peptide (substrate A)

To ([Cys-26]fluoresceinyl) peptide I was added 20 mM tetramethylrhodamine isothiocyanate (Molecular Probes, either R or G isomer or mixture) in DMSO to a final concentration of 2 mM and the reaction incubated at room temperature overnight in the dark. The mixture was desalted on a column of Sephadex G15 equilibrated in water. The UV/visible spectrum showed peaks of similar size at 495nm and 553nm indicating the presence of approximately equimolar amounts of both fluorescein and tetramethylrhodamine moieties in the peptide.

Preparation of dimethoxyfluorescein ([Cys-26]fluoresceinyl) peptide

- 11 -

'substrate B)

To ([Cys-26]fluoresceinyl) peptide I (0.58 ml) was added 0.116ml of 50mM dimethoxyfluorescein N-hydroxysuccinimide ester (prepared according to the method described in Anal. Biochem. 108, 156-161) in DMSC. After 2 hours, 0.5ml DMSO was added to re-dissolve some precipitated material and a further 2.0mg of the dimethoxyfluorescein reagent in DMSO (0.15ml) was added. After a further 2 hours, the product was isolated by passage through a column of Sephadex G15 (ca 10ml) equilibrated with 0.2M Tris.HCl buffer, pH 7.2:DMSO, 4:1. In addition to a fluorescein absorbance at 495nm, the UV spectrum of the product showed absorbance at 518nm, consistent with ca 1 mole/mole dimethoxyfluorescein.

Preparation of [Cys-26]eosinyl) peptide I

To a solution of peptide I in water (2mg/ml), was added an 1.1 equivalents of 5-maleimido-eosin (Molecular Probes, added as 5 mM solution in DMSO). After 15 minutes, 0.3 volumes of 0.1M NaHCO<sub>3</sub>, 0.9% NaCl buffer pH 8.5 added. After a further 15 minutes a sample was assayed for thiol content using Ellman's reagent. Since some free thiol was detected, a further 0.16 equivalents of 5-maleimido-eosin were added. After a further reaction period of ca 0.5 hours, the thiol content was found to be zero indicating complete coupling.

Preparation of fluoresceinyl [Cys-26]eosinyl) peptide I (substrate C)

To [Cys-26]eosinyl) peptide I was added fluorescein 5-isothiocyanate (Molecular Probes) in DMSO to a final concentration of 2.5 mg/ml and the reaction incubated at room temperature overnight in the dark. The mixture was desalting on a column of Sephadex G15 equilibrated in 0.2M Tris.HCl buffer pH 7.2. The UV/visible spectrum showed peaks of similar size at 495nm and 553nm indicating the presence of approximately equimolar amounts of both fluorescein and tetramethylrhodamine moieties in the peptide.

- 12 -

Evaluation of substrates

Samples of endothelin converting enzyme (ECE) were obtained according to the method of Okada et al., Biochem. Biophys. Res. Comm., 3, 1192-1198. A more purified sample, used to evaluate substrate C, was a gift of M Abbott (Zeneca).

Substrates at ca 10uM were incubated in 0.2M Tris.HCl buffer pH 7.2 and incubated with ECE at 37 degrees C in the wells of black microtitre plates (Labsystems). Fluorescein fluorescence was measured at various time intervals on a Labsystems Fluoroskan fluorescence plate reader, with excitation and emission filters set at 490 and 515nm respectively. After an initial incubation of ca 0.5 hours (to allow, it is believed, a stable meniscus to form) a linear increase in fluorescence was obtained. This is illustrated for substrate A in Figure 1. This also shows a control with no enzyme present, and also the effect of adding phosphoramidon, a known inhibitor of ECE, to a final concentration of 0.3mM.

The percentage conversion per unit time was calculated for each substrate and the results compared with the conversion of that preparation of ECE on big ET, as judged by high pressure liquid chromatography (hplc), which was found to be typically ca 25% conversion per hour. The activities of the three substrates were thereby found to be:

- 13 -

Position: N-terminus	Cys-26	Activity (big-ET-1)
substrate A tetramethylrhodamine	fluorescein	0.3-0.4
substrate B dimethoxyfluorescein	fluorescein	0.05
substrate C fluorescein	eosin	0.10-0.15

The three substrates show very different levels of activity. This indicates that the method of the invention may be readily used to investigate the activity of FRET protease substrates employing different fluorophores and acceptors.

#### Example 2

##### Preparation of starting peptides

The peptide sequences selected were:

1. For endothelin converting enzyme, human big endothelin-1, with Glu-26 changed to Cys:

H.His.Leu.Asp.Ile.Ile.Trp.Val.Asn.Thr.Pro.Cys.His.Val.Val.Pro.Tyr.Gly.  
Leu.Gly.Ser.Pro.Arg.OH      (Peptide I)

2. For staphylococcal V8 protease:

H.Arg.Asn.Ile.Thr.Glu.Gly.Glu.Ala.Arg.Gly.Ser.Val.Cys.Leu.OH  
(Peptide II)

The above peptides I and II were synthesised on polyamide supports using conventional Fmoc chemistry, as described in Solid

- 14 -

Phase Peptide Synthesis, E Atherton and R C Sheppard, IRL Press, 1989.

Preparation of [Cys-13]fluoresceinyl peptide II

To a solution of peptide II in water (2.5 mg/ml) was added an equimolar amount of S-maleimidofluorescein (Molecular Probes, added as a 13.3 mM solution in DMSO). After 10 minutes at room temperature, 0.3 volumes of 0.1M NaHCO<sub>3</sub>, pH 8.5 was added and the solution incubated for a further 15 minutes. A sample was assayed for thiol content using Ellman's reagents: this gave 98% loss of thiol indicating essentially complete coupling.

Preparation of tetramethylrhodaminyl [Cys-13]fluoresceinyl peptide II  
(substrate D)

To [Cys-13]fluoresceinyl peptide II was added 40mM tetramethylrhodamine isothiocyanate (Molecular Probes, isomer G) in DMSO to give a final concentration of 4.3 mM and the reaction mixture incubated at room temperature overnight in the dark. The mixture was then desalted on a column of Sephadex G15 equilibrated in water. The UV/visible spectrum showed peaks of similar size at 495nm and 553nm indicating the presence of approximately equimolar amounts of both fluorescein and tetramethylrhodamine moieties in the peptide.

Evaluation of the endothelin converting enzyme substrates  
(substrates A, B and C)

This was effected according to the protocol set out in Example 1.

Evaluation of the Staphylococcal V8 protease substrate (substrate D)

The staphylococcal V8 protease was obtained from the Pierce Chemical Co.

To a solution of substrate D (ca 0.5 micromolar in 0.2M

- 15 -

Tris-HCl buffer, pH 7.2, 0.6ml) in a fluorescence cuvette was added V8 protease (0.04ml, 300 units) and the increase in fluorescence monitored in a Spex Fluoromax fluorimeter with excitation at 495nm and emission at 515nm, and with an OD 1.0 neutral density filter and 5nm slit widths. The incubation was performed at ambient temperature.

Figure 2 shows the increase in fluorescence obtained. The reaction plateaus at a level ca 6.3 times higher than the initial level. Assuming complete conversion of substrate during the incubation, this implies that the substrate D was ca 84% quenched.

This shows that substrate D is a useful substrate for the estimation of the staphylococcal V8 protease.

- 15 -

CLAIMS:

1. A method for the preparation of a polypeptide substrate for proteolytic cleavage having a donor or acceptor species attached via a side chain of an amino acid therein which method comprises contacting a reactive donor or acceptor species with a polypeptide substrate having a side chain of an amino acid therein adapted for reaction therewith.

2. A method for the preparation of a polypeptide FRET substrate for proteolytic cleavage having donor and acceptor species on opposite sides of a proteolytic cleavage site and wherein the donor and/or acceptor species are attached via the side chain(s) of amino acid(s) therein which method comprises contacting a reactive donor or acceptor species with a polypeptide substrate having a corresponding donor or acceptor species attached via a side chain of an amino acid therein.

3. A method for the preparation of a polypeptide FRET substrate for proteolytic cleavage having donor and acceptor species on opposite sides of a proteolytic cleavage site and wherein the donor and/or acceptor species are attached via the side chain(s) of amino acid(s) therein which method comprises contacting a reactive donor or acceptor species with a polypeptide substrate having the side chain(s) of amino acid(s) therein adapted for reaction therewith, the polypeptide substrate already bearing the corresponding donor or acceptor species.

4. A method as claimed in any one of claims 1-3 wherein the site(s) for attachment of reactive donor and acceptor species are provided by amino and/or thiol groups.

5. A method as claimed in any one of claims 1-3 wherein the side chain of an amino acid in the polypeptide substrate for reaction with a reactive donor or acceptor species comprises a thiol group.

- 17 -

6. A method for the preparation of a polypeptide FRET substrate for proteolytic cleavage having donor and acceptor species on opposite sides of a proteolytic cleavage site and wherein the donor and/or acceptor species are attached via the side chain(s) of amino acid(s) therein which method comprises contacting a reactive donor or acceptor species with a polypeptide substrate having a side chain of an amino acid therein adapted via a thiol group for reaction therewith and then contacting an amino group of the polypeptide substrate so obtained with a corresponding donor or acceptor species.

7. A polypeptide substrate for proteolytic cleavage having a donor or acceptor species attached via a side chain of an amino acid therein.


8. A polypeptide FRET substrate for proteolytic cleavage having donor and acceptor species on opposite sides of a proteolytic cleavage site and wherein the donor and/or acceptor species are attached via the side chain(s) of amino acid(s) therein.


9. A polypeptide FRET substrate for proteolytic cleavage comprising a visible light fluorophore.

10. A polypeptide FRET substrate as claimed in claim 9 wherein the visible light fluorophore is attached via the side chain of an amino acid therein.

11. A method for the identification of modulators of protease activity which comprises the use of a polypeptide FRET substrate as claimed in any one of claims 8-10 or obtained according to a method as claimed in any one of claims 2-6.

1/2

FIGURE 1



## INTERNATIONAL SEARCH REPORT

International application No. PCT/GB 94/01153
--

A. CLASSIFICATION OF SUBJECT MATTER IPC 5 C12Q1/37 G01N33/533
--

According to International Patent Classification (IPC) or to both national classification and IPC:
--

B. FIELDS SEARCHED
--------------------

Minimum documentation searched (classification system followed by classification symbols) IPC 5 C12Q G01N
--

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
---

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
--

C. DOCUMENTS CONSIDERED TO BE RELEVANT
--

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. MED. CHEM., vol.35, no.21, 1992 pages 3727 - 3730 L.L.MAGGIORA ET AL. 'A General Method for the Preparation of Internally Quenched Fluorogenic Protease Substrates Using Solid-Phase Peptide Synthesis' cited in the application see the whole document ---	7,8,11 -/-

<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.
--

<input checked="" type="checkbox"/> Patent family members are listed in annex.
--

## \* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'I' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

- \*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- \*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- \*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- \*'A' document member of the same patent family

Date of the actual completion of the international search
---

21 September 1994
-------------------

Date of mailing of the international search report
--

26.09.94
----------

Name and mailing address of the ISA European Patent Office, P.B. 5018 Patentaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl. Fax (+ 31-70) 340-3016
--

Authorized officer
--------------------

Hitchen, C
------------

## INTERNATIONAL SEARCH REPORT

International application No. PCT/GB 94/01153
--

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BIOCONJUGATE CHEM., vol.4, no.6, 1993 pages 537 - 544 K.F.GEOGHEGAN ET AL. 'Site-Directed Double Fluorescent Tagging of Human Renin and Collagenase (MMP-1) Substrate Peptides Using the Periodate Oxidation of N-Terminal Serine. An Apparently General Strategy for Provision of Energy-Transfer Substrates for Proteases' see the whole document ---	1-4,7-11
A	WO,A,91 16336 (CARLSBERG A/S) 31 October 1991 see the whole document ---	1-11
A	US,A,5 011 910 (G.R.MARSHALL ET AL.) 30 April 1991 see the whole document ---	1-11
A	WO,A,92 00388 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 9 January 1992 see claims ---	1,2,9,10
A	FEBS LETTERS, vol.30, no.1, 1973 pages 11 - 14 A.CARMEL ET AL. 'Use of substrates with fluorescent donor and acceptor chromophores for the kinetic assay of hydrolases' cited in the application see page 11 - page 13 ---	1-8,11
A	TETRAHEDRON LETTERS, vol.31, no.45, 1990 pages 6493 - 6496 G.T.WANG ET AL. 'Design and synthesis of new fluorogenic HIV protease substrates based on resonance energy transfer' cited in the application see the whole document -----	1-11
2		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.  
PCT/GB 94/01153

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9116336	31-10-91	AU-A-	7751391	11-11-91
		EP-A-	0528854	03-03-93
US-A-5011910	30-04-91	EP-A-	0435845	03-07-91
		JP-A-	4210598	31-07-92
		US-A-	5164300	17-11-92
WO-A-9200388	09-01-92	EP-A-	0537270	21-04-93